Haemonetics (HAE) Reports Q1 Earnings: What Key Metrics Have to Say

Haemonetics (HAE) reported Q1 2025 results, with revenue of $321.39 million declining 4.4% year-over-year but exceeding consensus estimates by 5.97%. EPS of $1.10 also surpassed expectations by 8.91%. Despite the overall beat, key segment performance was mixed, with Plasma and Blood Center revenues down year-over-year, and the stock has recently underperformed the S&P 500.

Analysis

Haemonetics (HAE) presented a mixed financial picture for its first quarter ended June 2025, characterized by headline beats on earnings and revenue but underlying operational weakness. The company reported revenue of $321.39 million, a 4.4% year-over-year decline, yet surpassed the Zacks Consensus Estimate by 5.97%. Similarly, its EPS of $1.10 grew from $1.02 a year ago and beat consensus by 8.91%. A deeper look into the key segments reveals significant challenges. The Blood Center division experienced a severe 21.8% year-over-year revenue contraction, and the Plasma division, while beating analyst estimates, still saw its revenue fall 4.4% from the prior year. In contrast, the Hospital segment grew its revenue by 4.2% year-over-year but missed its specific analyst estimate. This operational softness is reflected in the stock's recent performance, with a -2.3% return over the past month, underperforming the S&P 500 composite's +1.2% gain and aligning with its neutral Zacks Rank #3 (Hold) rating.

Key Decisions for Investors

• Investors should look past the headline EPS and revenue beats and focus on the significant underlying weakness, particularly the 21.8% year-over-year revenue decline in the Blood Center segment and the 4.4% drop in Plasma.
• The stock's recent underperformance relative to the S&P 500 suggests the market is pricing in the operational challenges rather than the estimate surprises, warranting a cautious approach.
• Given the conflicting signals of strong earnings surprises against declining core revenues and a mixed segment performance, a neutral stance consistent with the Zacks #3 'Hold' rating is prudent pending signs of a sustainable revenue recovery.